SG11201605099YA - Injectable agent and depot formation method - Google Patents
Injectable agent and depot formation methodInfo
- Publication number
- SG11201605099YA SG11201605099YA SG11201605099YA SG11201605099YA SG11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA SG 11201605099Y A SG11201605099Y A SG 11201605099YA
- Authority
- SG
- Singapore
- Prior art keywords
- formation method
- injectable agent
- depot formation
- depot
- injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013266567 | 2013-12-25 | ||
PCT/JP2014/084289 WO2015099029A1 (en) | 2013-12-25 | 2014-12-25 | Injectable agent and depot formation method |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605099YA true SG11201605099YA (en) | 2016-07-28 |
Family
ID=53478876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605099YA SG11201605099YA (en) | 2013-12-25 | 2014-12-25 | Injectable agent and depot formation method |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160303240A1 (en) |
EP (1) | EP3088003A4 (en) |
JP (1) | JP6423263B2 (en) |
KR (1) | KR20160101905A (en) |
CN (1) | CN105792849A (en) |
CA (1) | CA2933150A1 (en) |
EA (1) | EA201691132A1 (en) |
GE (1) | GEP20186930B (en) |
PH (1) | PH12016501256A1 (en) |
SG (1) | SG11201605099YA (en) |
TW (1) | TW201609145A (en) |
WO (1) | WO2015099029A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6762158B2 (en) * | 2015-07-28 | 2020-09-30 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin or a derivative thereof |
EP3329916A4 (en) * | 2015-07-28 | 2019-03-20 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition including rapamycin or derivative thereof, and production method therefor |
JP6854639B2 (en) * | 2016-01-06 | 2021-04-07 | 日本化薬株式会社 | Pharmaceutical composition containing rapamycin derivative and method for producing the same |
KR20180036580A (en) | 2016-09-30 | 2018-04-09 | 주식회사 유스바이오팜 | Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid |
KR102252450B1 (en) * | 2017-02-09 | 2021-05-14 | 주식회사 아미코젠파마 | Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid |
CN115414324A (en) * | 2021-05-31 | 2022-12-02 | 中国科学院过程工程研究所 | Emulsion carrying local anesthetic and preparation method thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1336410A4 (en) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | Protein injection preparations |
JP2006503014A (en) * | 2002-08-20 | 2006-01-26 | プロテミックス コーポレイション リミティド | Dosage forms and related treatments |
CA2508303C (en) * | 2002-12-04 | 2012-10-23 | Santen Pharmaceutical Co., Ltd. | Drug delivery system using subconjunctival depot |
JP4496406B2 (en) | 2003-03-07 | 2010-07-07 | 参天製薬株式会社 | Novel compound having 4-pyridylalkylthio group as a substituent |
JP4626353B2 (en) | 2004-02-17 | 2011-02-09 | 参天製薬株式会社 | Novel cyclic compound having a 4-pyridylalkylthio group having a substituted or unsubstituted amino group introduced |
EA012205B1 (en) * | 2004-05-17 | 2009-08-28 | Арес Трейдинг С.А. | Hydrogel interferon formulations |
CA2588449A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Corporation | An implant for intraocular drug delivery |
JP4585978B2 (en) | 2005-03-03 | 2010-11-24 | 参天製薬株式会社 | Novel cyclic compounds having a quinolylalkylthio group |
JP4834441B2 (en) | 2005-03-31 | 2011-12-14 | 参天製薬株式会社 | Novel cyclic compounds having pyrimidinylalkylthio groups |
JP4825636B2 (en) | 2005-09-14 | 2011-11-30 | 参天製薬株式会社 | Novel 1,2-dihydroquinoline derivatives having glucocorticoid receptor binding activity |
JP5217136B2 (en) * | 2005-10-18 | 2013-06-19 | 大正製薬株式会社 | Semi-solid formulation for rectal, urethral and vaginal applications. |
US7700618B2 (en) | 2006-03-06 | 2010-04-20 | Pfizer Inc | Sulfonyl benzimidazole derivatives |
JP5054996B2 (en) | 2006-03-14 | 2012-10-24 | 参天製薬株式会社 | Novel 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity |
KR20090086539A (en) | 2006-11-14 | 2009-08-13 | 산텐 세이야꾸 가부시키가이샤 | Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents |
JP2008266295A (en) | 2007-01-29 | 2008-11-06 | Santen Pharmaceut Co Ltd | New thiadiazole derivative having kinase inhibitory activity |
CN101679317B (en) | 2007-05-29 | 2012-10-31 | 参天制药株式会社 | Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor binding activity |
JP2009084274A (en) | 2007-09-13 | 2009-04-23 | Santen Pharmaceut Co Ltd | New 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivative |
JP2010132587A (en) * | 2008-12-03 | 2010-06-17 | Teika Seiyaku Kk | Ophthalmic agent |
CN102471273B (en) | 2009-07-17 | 2014-07-16 | 参天制药株式会社 | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof |
RU2556340C2 (en) * | 2009-07-31 | 2015-07-10 | Санофи-Авентис Дойчланд Гмбх | Long-acting insulin composition |
JP5713791B2 (en) * | 2010-05-12 | 2015-05-07 | テイカ製薬株式会社 | Ophthalmic agent |
CA2809460C (en) * | 2010-09-03 | 2018-12-11 | Novagali Pharma Sa | A water-in-oil type emulsion for treating a disease of the eye |
US9469630B2 (en) * | 2010-10-18 | 2016-10-18 | Sumitomo Dainippon Pharma Co., Ltd. | Sustained-release formulation for injection |
IT1404145B1 (en) * | 2010-12-27 | 2013-11-15 | Altergon Sa | COMPOSITIONS OF HYALURONIC ACID STABILIZED TOWARDS THE DEGRADATION OF HEAT OR ENZYMES |
JP5931449B2 (en) * | 2012-01-11 | 2016-06-08 | 日東電工株式会社 | Pharmaceutical composition and method for producing the same |
CN102626381B (en) * | 2012-04-19 | 2013-05-29 | 海南灵康制药有限公司 | Vesicular phospholipid gel injection of latamoxef sodium |
-
2014
- 2014-12-24 TW TW103145137A patent/TW201609145A/en unknown
- 2014-12-25 CA CA2933150A patent/CA2933150A1/en not_active Abandoned
- 2014-12-25 CN CN201480065784.4A patent/CN105792849A/en active Pending
- 2014-12-25 GE GEAP201414194A patent/GEP20186930B/en unknown
- 2014-12-25 JP JP2014262257A patent/JP6423263B2/en not_active Expired - Fee Related
- 2014-12-25 KR KR1020167014611A patent/KR20160101905A/en not_active Application Discontinuation
- 2014-12-25 EP EP14874871.8A patent/EP3088003A4/en not_active Withdrawn
- 2014-12-25 EA EA201691132A patent/EA201691132A1/en unknown
- 2014-12-25 WO PCT/JP2014/084289 patent/WO2015099029A1/en active Application Filing
- 2014-12-25 SG SG11201605099YA patent/SG11201605099YA/en unknown
-
2016
- 2016-06-23 US US15/190,855 patent/US20160303240A1/en not_active Abandoned
- 2016-06-24 PH PH12016501256A patent/PH12016501256A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015143217A (en) | 2015-08-06 |
US20160303240A1 (en) | 2016-10-20 |
JP6423263B2 (en) | 2018-11-14 |
TW201609145A (en) | 2016-03-16 |
GEP20186930B (en) | 2018-12-10 |
CA2933150A1 (en) | 2015-07-02 |
KR20160101905A (en) | 2016-08-26 |
EP3088003A1 (en) | 2016-11-02 |
WO2015099029A1 (en) | 2015-07-02 |
PH12016501256A1 (en) | 2016-08-15 |
CN105792849A (en) | 2016-07-20 |
EA201691132A1 (en) | 2016-11-30 |
EP3088003A4 (en) | 2017-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2518057B (en) | Tracer and method | |
HUE053410T2 (en) | Application method and application facility | |
ZA201403959B (en) | Mine wifi and method | |
EP2952097A4 (en) | Pest-control composition and pest-control method | |
GB201306633D0 (en) | Biaising circuitry and method thereof | |
EP2952100A4 (en) | Pest-control composition and pest-control method | |
HUE039729T2 (en) | Variable-density composite articles and method | |
EP2970734A4 (en) | Compositions and method for refrigeration | |
GB201305414D0 (en) | Method and composition | |
EP2952099A4 (en) | Pest-control composition and pest-control method | |
SG11201605099YA (en) | Injectable agent and depot formation method | |
GB201300376D0 (en) | Method and compound | |
AP2016009013A0 (en) | Fairing and method | |
GB201313803D0 (en) | Fungicidal composition and method | |
HK1224348A1 (en) | Soil-volume reduction method | |
GB2584039B (en) | Container assembly and method | |
GB201515529D0 (en) | Injector and method | |
GB201415361D0 (en) | Hosiery and method | |
GB201320359D0 (en) | Assembly and method | |
GB201308285D0 (en) | Method and document | |
HK1222609A1 (en) | Gas barrier enhancing additives and methods | |
HUE035872T2 (en) | Storage and storage method | |
EP3001617A4 (en) | Entry adding method and switch | |
GB2522839B (en) | Method and document | |
GB2519994B (en) | Assemblies and methods |